Exact Sciences Stock Climbs After Strong Q2 Results
Exact Sciences Maintains Full-year 2024 Revenue Guidance Of $2.81B - $2.85B, Est $2.829B
TwinStrand Biosciences Enters Agreement With Exact Sciences To Exclusively License Its Patent Estate In The Cell Free Nucleic Acid Sequencing Space
Exact Sciences GAAP EPS of -$0.09 Beats by $0.24, Revenue of $699.26M Beats by $9.16M
Citigroup Maintains Buy on Incyte, Raises Price Target to $88
After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial
A Closer Look at AbbVie's Options Market Dynamics
Favorite High-yield Dividend Stocks - BMO
Cerevel Therapeutics Ticks Higher Amid Nasdaq Delisting Notice for AbbVie Deal
B of A Securities Maintains Neutral on Incyte, Raises Price Target to $66
Incyte Analyst Ratings
United Therapeutics GAAP EPS of $5.85 Misses by $0.55, Revenue of $714.9M Beats by $24.05M
PepGen Stock Tumbles 25% Following Release of DMD Drug Data
Exact Sciences Q2 2024 Earnings Preview
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Gilead Sciences's Options Frenzy: What You Need to Know
Incyte Drops 5 Clinical Drug Candidates Following Strategic Review
$100 Invested In This Stock 20 Years Ago Would Be Worth $600 Today
Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance
United Therapeutics Q2 2024 Earnings Preview